Eyebright Medical(SH:688050) Xin Lang Cai Jing·2025-11-04 05:46Core Viewpoint - Aibo Medical's stock has experienced a significant decline in 2023, with a year-to-date drop of 30.17% and a recent 5-day decline of 9.89% [1] Company Overview - Aibo Medical, established on April 21, 2010, and listed on July 29, 2020, is located in Changping District, Beijing. The company specializes in the research, production, and sales of ophthalmic medical devices [2] - The revenue composition of Aibo Medical includes: 43.86% from artificial lenses, 30.06% from contact lenses, 15.14% from orthokeratology lenses, 6.01% from other myopia control products, 2.37% from other surgical products, 1.62% from other vision care products, and 0.95% from other income [2] - Aibo Medical is categorized under the pharmaceutical and biological industry, specifically in medical devices and consumables, with concepts including ophthalmology, medical devices, medical aesthetics, specialized and innovative, and mid-cap [2] Financial Performance - For the period from January to September 2025, Aibo Medical reported a revenue of 1.144 billion yuan, reflecting a year-on-year growth of 6.43%. However, the net profit attributable to shareholders decreased by 8.64% to 290 million yuan [2] - Since its A-share listing, Aibo Medical has distributed a total of 241 million yuan in dividends, with 173 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Aibo Medical had 17,200 shareholders, an increase of 11.72% from the previous period. The average circulating shares per person decreased by 10.37% to 11,026 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 4.7962 million shares (a decrease of 980,000 shares), and Huabao Zhongzheng Medical ETF, holding 3.8663 million shares (a decrease of 550,000 shares) [3]